Dysfunctional high-density lipoprotein and atherosclerosis

Current Atherosclerosis Reports

Volumn 12, Issue 5, 2010, Pages 343-348

  Ragbir, Shawn ^a   Farmer, John A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Coronary artery disease (CAD); Dyslipidemia; High density lipoprotein (HDL); Hyperlipidemia; Lipid hypothesis; Low density lipoprotein (LDL)

Indexed keywords

CHOLESTEROL; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PEPTIDE DERIVATIVE; PROSTACYCLIN; SIMVASTATIN; TORCETRAPIB;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIUM; EXERCISE; FAT INTAKE; HEART PROTECTION; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; MACROPHAGE; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

ATHEROSCLEROSIS; DISEASE PROGRESSION; DYSLIPIDEMIAS; HUMANS; LIPOPROTEINS, HDL; PROGNOSIS; RISK FACTORS;

EID: 77956265233     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0091-x     Document Type: Review

References (41)

1. JW Gofman FT Lindgren H Elliott 1949 Ultracentrifugal studies of lipoproteins of human serum J Biol Chem 179 973 979 1:CAS:528: DyaH1MXktFGrsA%3D%3D 18150027
2. AM Scanu C Edelstein 2008 HDL: bridging past and present with a look at the future Faseb J 22 4044 4054 10.1096/fj.08-117150 1:CAS:528: DC%2BD1cXhsVKgurfI 18716026
3. JJ Link A Rohatgi JA de Lemos 2007 HDL cholesterol: physiology, pathophysiology, and management Curr Probl Cardiol 32 268 314 10.1016/j.cpcardiol.2007.01.004 17481993
4. M Florentin EN Liberopoulos AS Wierzbicki DP Mikhailidis 2008 Multiple actions of high-density lipoprotein Curr Opin Cardiol 23 370 378 10.1097/HCO.0b013e3283043806 18520722
5. GF Lewis DJ Rader 2005 New insights into the regulation of HDL metabolism and reverse cholesterol transport Circ Res 96 1221 1232 10.1161/01.RES. 0000170946.56981.5c 1:CAS:528:DC%2BD2MXltlSjt7Y%3D 15976321
6. CJ Fielding PE Fielding 1977 The activation of lipoprotein lipase by lipase co-protein (apo C-2) Expos Annu Biochim Med 33 165 172 1:CAS:528:DyaE1cXit1Kh 196908
7. GF Lewis 2006 Determinants of plasma HDL concentrations and reverse cholesterol transport Curr Opin Cardiol 21 345 352 10.1097/01.hco.0000231405. 76930.a0 16755204
8. HB Brewer Jr AT Remaley EB Neufeld, et al. 2004 Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease Arterioscler Thromb Vasc Biol 24 1755 1760 10.1161/01.ATV.0000142804.27420.5b 1:CAS:528:DC%2BD2cXotVOntr4%3D 15319263
9. S Yokoyama 2006 Assembly of high-density lipoprotein Arterioscler Thromb Vasc Biol 26 20 27 10.1161/01.ATV.0000195789.39418.e8 1:CAS:528: DC%2BD2MXhtlagt7jE 16284193
10. BL Trigatti M Krieger A Rigotti 2003 Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis Arterioscler Thromb Vasc Biol 23 1732 1738 10.1161/01.ATV.0000091363.28501.84 1:CAS:528:DC%2BD3sXnslWitr8%3D 12920050
11. PJ Barter JJ Kastelein 2006 Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease J Am Coll Cardiol 47 492 499 10.1016/j.jacc.2005.09.042 1:CAS:528:DC%2BD28XhtVGjs7k%3D 16458126
12. CC Schwartz JM Vanden Broek PS Cooper 2004 Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans J Lipid Res 45 1594 1607 10.1194/jlr.M300511-JLR200 1:CAS:528:DC%2BD2cXnvVWht7g%3D 15145983
13. A Kontush MJ Chapman 2006 Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis Pharmacol Rev 58 342 374 10.1124/pr.58.3.1 1:CAS:528:DC%2BD28XhtVOhtLfM 16968945
14. P Barter J Kastelein A Nunn R Hobbs 2003 High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions Atherosclerosis 168 195 211 10.1016/S0021-9150(03)00006-6 1:CAS:528:DC%2BD3sXksVOktbk%3D 12801602
15. M Gonzalez-Diez C Rodriguez L Badimon J Martinez-Gonzalez 2008 Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin Thromb Haemost 100 119 126 1:CAS:528:DC%2BD1cXhtFeiu73N 18612546 Pharmacologic therapy with statins has been demonstrated to improve endothelial function and maintain the integrity of the endothelium. Additionally, simvastatin has been shown to improve the HDL-mediated production of prostacyclin
16. BJ O'Connell J Genest Jr 2001 High-density lipoproteins and endothelial function Circulation 104 1978 1983 10.1161/hc3901.096667 11602504
17. M Navab GM Ananthramaiah ST Reddy, et al. 2004 The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL J Lipid Res 45 993 1007 10.1194/jlr.R400001-JLR200 1:CAS:528:DC%2BD2cXksFCksbk%3D 15060092
18. DN Nevin A Zambon CE Furlong, et al. 1996 Paraoxonase genotypes, lipoprotein lipase activity, and HDL Arterioscler Thromb Vasc Biol 16 1243 1249 1:CAS:528:DyaK28XmvF2hsLk%3D 8857920
19. X Moren S Deakin ML Liu, et al. 2008 HDL subfraction distribution of paraoxonase-1 and its relevance to enzyme activity and resistance to oxidative stress J Lipid Res 49 1246 1253 10.1194/jlr.M700439-JLR200 1:CAS:528: DC%2BD1cXmslWntbs%3D 18314464 HDL has been demonstrated to exist in a variety of subfractions that may have differing impacts on cardiovascular risk. The antioxidant effect of HDL is significant in reducing macrophage uptake of modified LDL. Antioxidant activity of HDL has been demonstrated to be distributed across the various subfractions that may impact protection from atherosclerosis
20. H Soran NN Younis V Charlton-Menys P Durrington 2009 Variation in paraoxonase-1 activity and atherosclerosis Curr Opin Lipidol 20 265 274 10.1097/MOL.0b013e32832ec141 1:CAS:528:DC%2BD1MXotFCjtbY%3D 19550323
21. SP Deakin RW James 2004 Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1 Clin Sci (Lond) 107 435 447 10.1042/CS20040187 1:CAS:528:DC%2BD2cXovVOhtLo%3D
22. S Campo MA Sardo G Trimarchi, et al. 2008 Platelet activating factor-acetylhydrolase (PAF-AH) activity and HDL levels, but not PAF-AH gene polymorphisms, are associated with successful aging in Sicilian octogenarians Aging Clin Exp Res 20 171 177 1:CAS:528:DC%2BD1cXnsVSisLY%3D 18431085
23. S Devaraj TW Du Clos I Jialal 2005 Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects Arterioscler Thromb Vasc Biol 25 1359 1363 10.1161/01.ATV.0000168573.10844.ae 1:CAS:528:DC%2BD2MXltlSitrY%3D 15860734
24. CM Ballantyne 2002 Soluble adhesion molecules and coronary heart disease Lancet 359 525 10.1016/S0140-6736(02)07644-4 11853824 author reply 6-7
25. GW Cockerill KA Rye JR Gamble, et al. 1995 High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules Arterioscler Thromb Vasc Biol 15 1987 1994 1:CAS:528:DyaK28XhslCnuw%3D%3D 7583580
26. M Tolle A Pawlak M Schuchardt, et al. 2008 HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production Arterioscler Thromb Vasc Biol 28 1542 1548 10.1161/ATVBAHA.107.161042 18483405
27. NE Miller DS Thelle OH Forde OD Mjos 1977 The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study Lancet 1 965 968 10.1016/S0140-6736(77)92274-7 1:STN:280: DyaE2s7mvF2lsA%3D%3D 67464
28. T Gordon WP Castelli MC Hjortland, et al. 1977 High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 707 714 10.1016/0002-9343(77)90874-9 1:CAS:528:DyaE2sXhvVOhtbg%3D 193398
29. PJ Barter M Caulfield M Eriksson, et al. 2007 Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2109 2122 10.1056/NEJMoa0706628 1:CAS:528:DC%2BD2sXhtlGns7bL 17984165
30. PO Kwiterovich Jr 1998 The antiatherogenic role of high-density lipoprotein cholesterol Am J Cardiol 82 13Q 21Q 10.1016/S0002-9149(98)00808-X 1:CAS:528:DyaK1cXns1GqsL4%3D 9819099
31. BJ Ansell GC Fonarow AM Fogelman 2007 The paradox of dysfunctional high-density lipoprotein Curr Opin Lipidol 18 427 434 10.1097/MOL. 0b013e3282364a17 1:CAS:528:DC%2BD2sXnsVCkurY%3D 17620860
32. M Navab SY Hama CJ Cooke, et al. 2000 Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1 J Lipid Res 41 1481 1494 1:CAS:528:DC%2BD3cXntValtbs%3D 10974056
33. SJ Nicholls P Lundman JA Harmer, et al. 2006 Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function J Am Coll Cardiol 48 715 720 10.1016/j.jacc.2006.04.080 1:CAS:528:DC%2BD28XotFWksb8%3D 16904539
34. M Navab SY Hama GP Hough, et al. 2001 A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids J Lipid Res 42 1308 1317 1:CAS:528:DC%2BD3MXlvFeksLk%3D 11483633
35. MP Stern 1995 Diabetes and cardiovascular disease. The "common soil" hypothesis Diabetes 44 369 374 10.2337/diabetes.44.4.369 1:CAS:528:DyaK2MXkslOjs74%3D 7698502
36. S Yamashita T Maruyama K Hirano, et al. 2000 Molecular mechanisms, lipoprotein abnormalities and atherogenicity of hyperalphalipoproteinemia Atherosclerosis 152 271 285 10.1016/S0021-9150(00)00574-8 1:CAS:528: DC%2BD3cXms1WktrY%3D 10998455
37. MS Gowri DR Van der Westhuyzen SR Bridges JW Anderson 1999 Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL Arterioscler Thromb Vasc Biol 19 2226 2233 1:CAS:528:DyaK1MXmtFOrtL0%3D 10479666
38. B Hansel P Giral E Nobecourt, et al. 2004 Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity J Clin Endocrinol Metab 89 4963 4971 10.1210/jc.2004-0305 1:CAS:528: DC%2BD2cXovVemsrg%3D 15472192
39. CK Roberts C Ng S Hama AJ Eliseo RJ Barnard 2006 Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors J Appl Physiol 101 1727 1132 10.1152/japplphysiol.00345.2006 1:CAS:528:DC%2BD28Xhtlent7bE 16902063
40. JK Liao U Laufs 2005 Pleiotropic effects of statins Annu Rev Pharmacol Toxicol 45 89 118 10.1146/annurev.pharmtox.45.120403.095748 1:CAS:528: DC%2BD2MXisVWjtrY%3D 15822172
41. M Navab GM Anantharamaiah ST Reddy, et al. 2004 Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice Circulation 109 3215 3220 10.1161/01.CIR.0000134275.90823.87 1:CAS:528:DC%2BD2cXltVCgtrg%3D 15197147